0001104659-15-049012.txt : 20150630 0001104659-15-049012.hdr.sgml : 20150630 20150630184533 ACCESSION NUMBER: 0001104659-15-049012 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150630 FILED AS OF DATE: 20150630 DATE AS OF CHANGE: 20150630 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CATABASIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001454789 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BLDG. 1400E, SUITE B14202 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-349-1971 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BLDG. 1400E, SUITE B14202 CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MedImmune Ventures, Inc. CENTRAL INDEX KEY: 0001291884 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37467 FILM NUMBER: 15962715 BUSINESS ADDRESS: STREET 1: ONE MEDIMMUNE WAY CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 301-398-0000 MAIL ADDRESS: STREET 1: ONE MEDIMMUNE WAY CITY: GAITHERSBURG STATE: MD ZIP: 20878 4 1 a4.xml 4 X0306 4 2015-06-30 0 0001454789 CATABASIS PHARMACEUTICALS INC CATB 0001291884 MedImmune Ventures, Inc. ONE MEDIMMUNE WAY GAITHERSBURG MD 20878 0 0 1 0 Common Stock 2015-06-30 4 C 0 1079115 A 1079115 D Common Stock 2015-06-30 4 C 0 330098 A 1409213 D Common Stock 2015-06-30 4 P 0 223439 12 A 1632652 D Series A Preferred Stock 2015-06-30 4 C 0 13866666 0 D Common Stock 1079115 0 D Series B Preferred Stock 2015-06-30 4 C 0 4241780 0 D Common Stock 330098 0 D The Series A and Series B Preferred Stock converted into Common Stock on a 1-for-12.85 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A and B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. These shares are owned directly by MedImmune Ventures, Inc. Ron Laufer is the Senior Managing Partner of MedImmune Ventures, Inc., and as a result, Dr. Laufer may be deemed to hold voting, dispositive and investment power over the shares held by MedImmune Ventures, Inc. Dr. Laufer disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. /s/ Andrea Matthews, attorney-in-fact for MedImmune Ventures, Inc. 2015-06-30